Correction to: Differentiating Cardiac Troponin Levels During Cardiac Myosin Inhibition or Cardiac Myosin Activation Treatments: Drug Effect or the Canary in the Coal Mine?
(Source: Current Heart Failure Reports)
Source: Current Heart Failure Reports - December 1, 2023 Category: Cardiology Source Type: research
Cardiac CT Beyond Coronaries: Focus on Structural Heart Disease
AbstractPurpose of ReviewCardiac computed tomography (CT) is an established non-invasive imaging tool for the assessment of coronary artery disease. Furthermore, it plays a key role in the preinterventional work-up of patients presenting with structural heart disease.Recent FindingsCT is the gold standard for preprocedural annular assessment, device sizing, risk determination of annular injury, coronary occlusion or left ventricular outflow tract obstruction, calcification visualization and quantification of the target structure, and prediction of a co-planar fluoroscopic angulation for transcatheter interventions in patie...
Source: Current Heart Failure Reports - November 29, 2023 Category: Cardiology Source Type: research
Your Heart Function Has Normalized —What Next After TRED-HF?
AbstractPurpose of ReviewWith the widespread implementation of contemporary disease-modifying heart failure therapy, the rates of normalization of ejection fraction are continuously increasing. The TRED-HF trial confirmed that heart failure remission rather than complete recovery is typical in patients with dilated cardiomyopathy who respond to therapy. The present review outlines key points related to the management and knowledge gaps of this growing patient group, focusing on patients with non-ischaemic dilated cardiomyopathy.Recent FindingsThere is substantial heterogeneity among patients with normalized ejection fracti...
Source: Current Heart Failure Reports - November 24, 2023 Category: Cardiology Source Type: research
Towards Allograft Longevity: Leveraging Omics Technologies to Improve Heart Transplant Outcomes
AbstractPurpose of ReviewHeart transplantation (HT) remains the optimal therapy for patients living with end-stage heart disease. Despite recent improvements in peri-transplant management, the median survival after HT has remained relatively static, and complications of HT, including infection, rejection, and allograft dysfunction, continue to impact quality of life and long-term survival.Recent FindingsOmics technologies are becoming increasingly accessible and can identify novel biomarkers for, and reveal the underlying biology of, several disease states. While some technologies, such as gene expression profiling (GEP) a...
Source: Current Heart Failure Reports - November 15, 2023 Category: Cardiology Source Type: research
Heart Failure and Erectile Dysfunction: a Review of the Current Evidence and Clinical Implications
AbstractPurpose of ReviewHeart failure (HF) and erectile dysfunction (ED) are two common conditions that affect millions of men worldwide and impair their quality of life. ED is a frequent complication of HF, as well as a possible predictor of cardiovascular events and mortality. ED deserves more attention from clinicians and researchers.Recent FindingsThe pathophysiology of ED in HF involves multiple factors, such as endothelial dysfunction, reduced cardiac output, neurohormonal activation, autonomic imbalance, oxidative stress, inflammation, and drug side effects. The diagnosis of ED in HF patients should be based on val...
Source: Current Heart Failure Reports - November 14, 2023 Category: Cardiology Source Type: research
Differentiating Cardiac Troponin Levels During Cardiac Myosin Inhibition or Cardiac Myosin Activation Treatments: Drug Effect or the Canary in the Coal Mine?
AbstractPurpose of ReviewCardiac myosin inhibitors (CMIs) and activators are emerging therapies for hypertrophic cardiomyopathy (HCM) and heart failure with reduced ejection fraction (HFrEF), respectively. However, their effects on cardiac troponin levels, a biomarker of myocardial injury, are incompletely understood.Recent FindingsIn patients with HCM, CMIs cause substantial reductions in cardiac troponin levels which are reversible after stopping treatment. In patients with HFrEF, cardiac myosin activator (omecamtiv mecarbil) therapy cause modest increases in cardiac troponin levels which are reversible following treatme...
Source: Current Heart Failure Reports - October 25, 2023 Category: Cardiology Source Type: research
Hydrogels for Cardiac Restorative Support: Relevance of Gelation Mechanisms for Prospective Clinical Use
AbstractPurpose of ReviewCardiac tissue regenerative strategies have gained much traction over the years, in particular those utilizing hydrogels. With our review, and with special focus on supporting post-myocardial infarcted tissue, we aim to provide insights in determining crucial design considerations of a hydrogel and the implications these could have for future clinical use.Recent FindingsTo date, two hydrogel delivery strategies are being explored, cardiac injection or patch, to treat myocardial infarction. Recent advances have demonstrated that the mechanism by which a hydrogel is gelated (i.e., physically or chemi...
Source: Current Heart Failure Reports - October 9, 2023 Category: Cardiology Source Type: research
The Right Heart in Congenital Heart Disease
AbstractPurpose of ReviewTo analyze the pathophysiologic importance of the right heart in different types of congenital heart disease (CHD), summarize current diagnostic modalities, and discuss treatment options.Recent FindingsThe right ventricle (RV) plays a key role in disease progression and prognosis, either as the subpulmonary or as the systemic ventricle. Volume and/or pressure overload as well as intrinsic myocardial disease are the main factors for RV remodeling. Echocardiography and cardiac magnetic resonance imaging are important noninvasive modalities for assessing anatomy, size, and function of the right heart....
Source: Current Heart Failure Reports - September 29, 2023 Category: Cardiology Source Type: research
Natriuretic Peptide Receptors (NPRs) as a Potential Target for the Treatment of Heart Failure
AbstractPurpose of ReviewHeart failure is defined as a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood. The natriuretic peptide is known to exert its biological action on the kidney, heart, blood vessels, renin –angiotensin system, autonomous nervous system, and central nervous system. The natriuretic peptide–natriuretic receptor system plays an important role in the regulation of blood pressure and body fluid volume through its pleiotropic effects.Recent FindingsThe clinical and animal studies suggest that natriuretic peptide –natriureti...
Source: Current Heart Failure Reports - September 15, 2023 Category: Cardiology Source Type: research
Perspectives on Secondary Mitral Regurgitation in Heart Failure
AbstractPurpose of the ReviewThis review focuses on broader perspectives of mitral regurgitation (MR) in patients with heart failure.Recent FindingsThe ratio of regurgitant volume to end-diastolic volume appears to help identify patients who may benefit from valve interventions. Secondary MR is not only attributed to geometric changes of the LV but also related to the structural changes in the mitral valve that include fibrosis of the mitral leaflets and changes in the extracellular matrix. The transition from mild to severe secondary MR can occur at different rates, from a slow LV remodeling process to a more abrupt proce...
Source: Current Heart Failure Reports - September 11, 2023 Category: Cardiology Source Type: research
Do Heart Failure Biomarkers Influence Heart Failure Treatment Response?
AbstractPurpose of ReviewHeart failure (HF) is one of the leading causes of cardiac morbidity and mortality around the world. Our evolving understanding of the cellular and molecular pathways of HF has led to the identification and evaluation of a growing number of HF biomarkers. Natriuretic peptides remain the best studied and understood HF biomarkers, with demonstrated clinical utility in the diagnosis and prognostication of HF. Less commonly understood is the utility of HF biomarkers for guiding and monitoring treatment response. In this review, we outline the current HF biomarker landscape and identify novel biomarkers...
Source: Current Heart Failure Reports - September 7, 2023 Category: Cardiology Source Type: research
